EcoDrugPlus

Probable Histone Deacetylase 1-B

Ensembl ID : ENSMAMG00000010154
Gene Symbol: LOC113131002
2 Cross references
255 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSMAMG00000013413
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor 2-Like

Ensembl ID : ENSMAMG00000024949
Gene Symbol: LOC113127904
2 Cross references
145 Possible Orthologues:

Prostaglandin D2 Receptor 2-Like

Ensembl ID : ENSMAMG00000006752
Gene Symbol: LOC113143872
3 Cross references
135 Possible Orthologues:

Prostaglandin E Receptor 1a (Subtype Ep1)

Ensembl ID : ENSMAMG00000008071
Gene Symbol: PTGER1A
3 Cross references
167 Possible Orthologues:

Prostaglandin E Receptor 2a (Subtype Ep2)

Ensembl ID : ENSMAMG00000027924
Gene Symbol: PTGER2A
1 Cross references
202 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSMAMG00000026906
Gene Symbol: PTGER3
3 Cross references
194 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) A

Ensembl ID : ENSMAMG00000019542
Gene Symbol: PTGER4A
3 Cross references
202 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSMAMG00000010592
Gene Symbol: LOC113140579
3 Cross references
164 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSMAMG00000018540
Gene Symbol: LOC113124783
3 Cross references
201 Possible Orthologues:

Prostaglandin F Receptor (Fp)

Ensembl ID : ENSMAMG00000001521
Gene Symbol: PTGFR
3 Cross references
195 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSMAMG00000011128
Gene Symbol: PTGIR
2 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).